Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $6,130.5M | $6,044.4M | $3,714.9M | $11.1B | $5,180.0M | ($7,590.4M) | $4,025.0M | $2,358.0M | $3,817.0M | $1,357.0M | $12.5B | $1,594.0M | $3,576.0M | $3,629.0M | $5,731.0M | $9,227.0M | $6,076.0M | $13.7B | $19.4B | $2,954.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Merck & Co., Inc.'s last 12-month Operating Income is $14.9B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Merck & Co., Inc.'s Operating Income growth was 66.1%. The average annual Operating Income growth rates for Merck & Co., Inc. have been 32.9% over the past three years, 3.4% over the past five years.
Over the last year, Merck & Co., Inc.'s Operating Income growth was 66.1%, which is higher than industry growth of 0.0%. It indicates that Merck & Co., Inc.'s Operating Income growth is Good.